Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
1.070
-0.010 (-0.93%)
At close: May 22, 2026, 4:00 PM EDT
1.090
+0.020 (1.87%)
After-hours: May 22, 2026, 6:13 PM EDT
Revelation Biosciences Stock Forecast
REVB's stock price has decreased by -96.52% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, Revelation Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $19.25. The average 1-year stock price forecast is 1,699.07% higher than the current stock price, while the lowest is $16 (+1,395.33%) and the highest is $22.5 (+2,002.80%).
Price Target: $19.25 (+1,699.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Revelation Biosciences is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $28,800 → $86,400 | Strong Buy | Maintains | $28,800 → $86,400 | +8,074,666.36% | Feb 14, 2023 |
| Roth Capital | Roth Capital | Strong Buy Initiates $2,419,200 | Strong Buy | Initiates | $2,419,200 | +226,093,357.94% | Feb 17, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.09
from -23.95
EPS Next Year
-3.69
from -5.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -5.03 | -3.14 | ||||
| Avg | -5.09 | -3.69 | ||||
| Low | -5.10 | -4.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.